Evidence map›Paper›PMID 41555244›Full record

Observational studyBMC infectious diseases2026

Microbiological characterization and clinical outcomes of carbapenem-resistant enterobacterales infections in a paediatric hospital in Mexico.

Jocelin Merida-Vieyra, Alejandra Aquino-Andrade, Alejandro Tapia-Reyes, Óscar Alberto Pérez-González, Héctor E A Méndez, Ruben Bautista-Hernandez, Agustín De Colsa-Ranero, Gerardo Aparicio-Ozores, Laura Belmont-Monroy

Abstract readObservational Study
In one paragraph

Observational study in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jocelin Merida-VieyraMolecular Microbiology Laboratory, Instituto Nacional de Pediatría, Insurgentes Sur 3700-C, Alcaldia Coyoacán, Coyoacán, Mexico City, CP 04530, Mexico.
Alejandra Aquino-AndradeMolecular Microbiology Laboratory, Instituto Nacional de Pediatría, Insurgentes Sur 3700-C, Alcaldia Coyoacán, Coyoacán, Mexico City, CP 04530, Mexico. aaquinoa@pediatria.gob.mx.
Alejandro Tapia-ReyesBacteriology Laboratory, Instituto Nacional de Pediatría, Coyoacan, Mexico City, Mexico.
Óscar Alberto Pérez-GonzálezExperimental Oncology Laboratory, Instituto Nacional de Pediatría, Coyoacán Mexico City, Mexico.
Héctor E A MéndezMolecular Microbiology Laboratory, Instituto Nacional de Pediatría, Insurgentes Sur 3700-C, Alcaldia Coyoacán, Coyoacán, Mexico City, CP 04530, Mexico.
Ruben Bautista-HernandezMolecular Microbiology Laboratory, Instituto Nacional de Pediatría, Insurgentes Sur 3700-C, Alcaldia Coyoacán, Coyoacán, Mexico City, CP 04530, Mexico.
Agustín De Colsa-RaneroDepartment of Infectious Diseases, Instituto Nacional de Pediatría, Coyoacán Mexico City, Mexico.
Gerardo Aparicio-OzoresBacteriology Laboratory, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Miguel Hidalgo Mexico City, Mexico.
Laura Belmont-MonroyMolecular Microbiology Laboratory, Instituto Nacional de Pediatría, Insurgentes Sur 3700-C, Alcaldia Coyoacán, Coyoacán, Mexico City, CP 04530, Mexico.

Funding

Modality A of the fiscal resource of the National Institute of Paediatrics 2018-2022 INP 2018/017SECIHTI FOSISS 2018-1-289537
6 · The paper itself

Abstract

backgroundThe mortality rate in children with carbapenem-resistant Enterobacterales (CRE) infections can exceed 50%, depending on the origin of the infection, antimicrobial resistance, comorbidities, and drug availability. This study aimed to describe the clonal diversity of CRE, as well as the clinical characteristics, treatments, and outcomes of the infections in pediatric patients in a tertiary care hospital in Mexico.

methodsThis single-centre observational study was conducted in a paediatric tertiary care hospital, in which 40 CRE isolates were included; the susceptibility profile and phenotypic and genotypic detection of carbapenemases were determined. The sequence type (ST) was obtained by multilocus sequence typing, and the clinical records were reviewed to obtain clinical information.

resultsKlebsiella spp. and Escherichia coli were the predominant species (35 and 29%, respectively). A total of 57.5% of the isolates were susceptible to ceftazidime-avibactam (CZA). 70% of the isolates were carbapenemase-producing Enterobacterales (CPE). The most frequent enzymes were NDM-like (52%), OXA-48 like (24%), KPC-2 (17%), and VIM-2 (7%); NDM-5 and OXA-48 were detected in an E. coli isolate. 36% of the CRE isolates were considered high-risk clones (HRC); E. coli ST167 and K. pneumoniae ST15 and ST25 were the most frequent clones. The most common infections were pneumonia (25%) and bacteraemia (17.5%). 90% of the patients had some underlying disease. Empirical treatment was administered to 34 patients, 19 in monotherapy and 15 in combined therapy. A total of 47.5% of the patients died. Carbapenemase production was related to admission to the intensive care unit (ICU) (p = 0.043) and the presentation of complications (p = 0.032). Patients who experienced complications required admission to the ICU (p = 0.02) and exhibited higher mortality rates (p = 0.046).

conclusionsK. pneumoniae was the predominant species identified. At least one carbapenemase was detected in 70% of the CRE isolates; the most frequent enzyme was NDM. This study reports the first isolations of E. coli ST167-NDM-5 and K. pneumoniae ST231-NDM-1 in Mexican pediatric patients. Pneumonia was the most frequent infection. The lack of availability of new antimicrobials in our hospital limits therapeutic options, which may have contributed to the high mortality rate (47.5%) observed. CLINICAL TRIAL: Not applicable.

Indexed as

Carbapenem-Resistant EnterobacteriaceaeEnterobacteriaceae InfectionsAdolescentAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesCarbapenemsChildChild, PreschoolEscherichia coliFemaleHospitals, PediatricHumansInfantMaleMexicoAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasescarbapenemaseCarbapenemsCarbapenemase-producing EnterobacteralesMexicoNDM-1NDM-5OXA-48PaediatricsVIM-2

Identifiers

PMID41555244
PMCPMC12895847

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.